News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,119 Results
Type
Article (13818)
Company Profile (101)
Press Release (252200)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88112)
Career Advice (473)
Deals (15348)
Drug Delivery (67)
Drug Development (36614)
Employer Resources (49)
FDA (6301)
Job Trends (6202)
News (150324)
Policy (14052)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (442)
Accelerated approval (2)
Adcomms (6)
Allergies (35)
Alliances (23244)
ALS (37)
Alzheimer's disease (393)
Antibody-drug conjugate (ADC) (42)
Approvals (6339)
Artificial intelligence (110)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (641)
Cardiovascular disease (72)
Career advice (413)
Career pathing (12)
CAR-T (22)
Cell therapy (89)
Cervical cancer (4)
Clinical research (30952)
Collaboration (352)
Compensation (155)
Complete response letters (17)
COVID-19 (758)
CRISPR (21)
C-suite (126)
Cystic fibrosis (37)
Data (663)
Denatured (15)
Depression (9)
Diabetes (83)
Diagnostics (1325)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32217)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37591)
Executive appointments (397)
FDA (6733)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (215)
Gene editing (39)
Generative AI (9)
Gene therapy (101)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (17)
Healthcare (3566)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (36)
Indications (14)
Infectious disease (794)
Inflammatory bowel disease (56)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (61)
IPO (5881)
IRA (29)
Job creations (2051)
Job search strategy (378)
Kidney cancer (6)
Labor market (12)
Layoffs (180)
Leadership (3)
Legal (3434)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (161)
MASH (33)
Medical device (1286)
Medtech (1288)
Mergers & acquisitions (9678)
Metabolic disorders (265)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (582)
NextGen: Class of 2025 (1586)
Non-profit (604)
Northern California (737)
Now hiring (8)
Obesity (151)
Opinion (119)
Ovarian cancer (22)
Pain (52)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (120)
Patient recruitment (29)
Peanut (10)
People (28995)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8054)
Phase II (13100)
Phase III (11747)
Pipeline (463)
Policy (72)
Postmarket research (1401)
Preclinical (3230)
Press Release (25)
Prostate cancer (48)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (171)
Real estate (2638)
Recruiting (17)
Regulatory (10148)
Reports (14)
Research institute (566)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (37)
Series B (13)
Service/supplier (3)
Sickle cell disease (32)
Southern California (744)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1636)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (30)
The Weekly (30)
United States (7405)
Vaccines (155)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (3)
Date
Today (71)
Last 7 days (268)
Last 30 days (931)
Last 365 days (11771)
2025 (3842)
2024 (12514)
2023 (14265)
2022 (19565)
2021 (20069)
2020 (19038)
2019 (14892)
2018 (11723)
2017 (13896)
2016 (13132)
2015 (15477)
2014 (12425)
2013 (10596)
2012 (11404)
2011 (11931)
2010 (10896)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (56)
Arkansas (3)
Asia (20149)
Australia (2617)
California (1779)
Canada (928)
China (247)
Colorado (71)
Connecticut (70)
Delaware (60)
Europe (39516)
Florida (337)
Georgia (38)
Idaho (9)
Illinois (200)
India (16)
Indiana (136)
Iowa (1)
Japan (94)
Kansas (58)
Kentucky (12)
Louisiana (1)
Maine (2)
Maryland (263)
Massachusetts (1520)
Michigan (30)
Minnesota (95)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (8)
New Hampshire (6)
New Jersey (780)
New Mexico (7)
New York (527)
North Carolina (401)
North Dakota (2)
Northern California (737)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (458)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (744)
Tennessee (34)
Texas (236)
Utah (34)
Virginia (76)
Washington D.C. (31)
Washington State (123)
Wisconsin (17)
266,119 Results for "portola pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
·
6 min read
Press Releases
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 26, 2025
·
15 min read
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Deals
Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) to Alexion Pharmaceuticals, Inc. for $18 per share in cash is fair to Portola shareholders.
May 5, 2020
·
1 min read
Business
Former Portola CEO Takes the Helm at T-Cell Cancer Therapy Company
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
March 5, 2021
·
3 min read
·
Alex Keown
Policy
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.
May 5, 2020
·
1 min read
1 of 26,612
Next
